Using continuous glucose monitoring to manage diabetes after starting insulin
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
This study tests whether using a continuous glucose monitor can help people with type 1 or type 2 diabetes manage their blood sugar better after starting insulin therapy compared to using a traditional blood glucose monitor.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | NYU Langone Health Academic / other |
| Locations | 1 site (Mineola, New York) |
| Trial ID | NCT05548205 on ClinicalTrials.gov |
What this trial studies
This study involves a randomized, prospective approach with 120 participants who have type 1 or type 2 diabetes and are newly starting insulin therapy upon hospital discharge. Participants will be assigned to either use a continuous glucose monitor (CGM) for two weeks or a traditional blood glucose monitor (BGM) for the same duration. Follow-up visits will occur at two weeks and three months to adjust insulin doses as necessary and measure HbA1c levels. The goal is to evaluate the effectiveness of CGM in improving glycemic management compared to BGM.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-100 with a known history of type 1 or type 2 diabetes who are starting insulin therapy upon hospital discharge.
Not a fit: Patients who have previously used insulin therapy or are currently on systemic corticosteroids will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved glycemic control for patients newly initiated on insulin therapy.
How similar studies have performed: Other studies have shown promising results with continuous glucose monitoring in diabetes management, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female aged 18-100 years 2. Known history of type 1 or type 2 diabetes 3. Admitted to NYU Langone Hospital - Long Island between December 16, 2024- December 31, 2026 4. New initiation of insulin therapy, including basal insulin regimen, basal-bolus insulin regimen, or mixed insulin regimen at the time of hospital discharge Exclusion Criteria: 1. Prior to admission use of home insulin therapy 2. Current use of systemic corticosteroids 3. Active pregnancy; as pregnancy requires different blood glucose targets, subjects known to be pregnant will be excluded from this study. Subjects will not be tested for pregnancy outside of testing performed in routine medical care; pregnancy will be determined by patient self-reporting. Females of childbearing potential will not be instructed to avoid pregnancy, however if they became pregnant during the study (detected by self-reporting), they will be withdrawn from the study.
Where this trial is running
Mineola, New York
- NYU Langone Hospital - Long Island — Mineola, New York, United States (Recruiting)
Study contacts
- Principal investigator: Michael Goldstein — NYU Langone Hospital - Long Island
- Study coordinator: Michael Goldstein
- Email: Michael.Goldstein@nyulangone.org
- Phone: 516-663-3511
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.